Feline Cholangitis: Welfare and Management

Cholangitis (bile duct and liver inflammation) is a significant welfare condition in cats that often presents alongside inflammatory bowel disease and pancreatitis — the 'triaditis' complex.

Key Facts

Neutrophilic cholangitis is caused by ascending bacterial infection from the intestine — treatment requires antibiotics and is often curative
Lymphocytic cholangitis is an immune-mediated condition requiring long-term immunosuppressive management
Cholangitis is the second most common liver disease in cats after hepatic lipidosis
The combination of cholangitis, inflammatory bowel disease and pancreatitis (triaditis) is a recognised welfare challenge requiring multi-system management

Welfare Considerations

Cholangitis welfare impacts include jaundice, nausea, reduced appetite, abdominal pain and weight loss. The welfare burden of triaditis is cumulative — managing three simultaneous inflammatory conditions requires sustained, multimodal treatment. Cats with chronic lymphocytic cholangitis require lifelong ursodeoxycholic acid and immunosuppression, creating ongoing treatment welfare costs. Careful monitoring of response using liver enzyme trends and clinical signs allows dose optimisation that balances disease control against treatment burden.

What You Can Do

Seek investigation of any cat with persistent jaundice, vomiting or weight loss — cholangitis diagnosis requires ultrasound and ideally biopsy
Treat neutrophilic cholangitis aggressively with appropriate antibiotics — culture-guided therapy improves outcomes
Begin ursodeoxycholic acid alongside immunosuppression for lymphocytic cholangitis — this combination improves welfare outcomes
Monitor liver enzyme trends every 3-6 months to guide long-term treatment adjustments in chronic cases